Literature DB >> 23135568

Injectable administration privileges among pharmacists in the United States.

Valerie Oji1, Yolanda McKoy-Beach, Tiffany Pagan, Barbara Matike, Oluwaranti Akiyode.   

Abstract

PURPOSE: Privileges for administering nonvaccine injectable medications among pharmacists in the United States were assessed.
METHODS: An e-mail inquiry on specific protocols for the administration of injectables was sent to the state boards of pharmacy (BOPs) for all 50 states and the District of Columbia that had a valid e-mail address listed on the National Association of Boards of Pharmacy website. Respondents were encouraged to include in their response a link to state regulations so that information from the BOP laws on privileges for administering injectables could be closely reviewed. State guidelines were reviewed online for all BOPs that did not respond to the first e-mail in order to complete the study. A follow-up e-mail was sent only to those respondents whose states granted pharmacists privileges for administering nonvaccine injectables in order to clarify the specific drugs allowed to be injected by pharmacists.
RESULTS: Responses received included either links to state regulations or explicit statements of the rules regarding pharmacists' injectable privileges. A total of 21 states currently grant pharmacists articulate written information or rules pertaining to the privilege of administering nonvaccine injectable products. Authority is provided through collaborative practice agreements for most states. Products administered by pharmacists vary by state.
CONCLUSION: Pharmacists in 21 states were found to have privileges for administering injectable medications other than vaccines. Pharmacists were authorized to administer these drugs through completion of training approved by the Accreditation Council for Pharmacy Education, collaborative practice agreements, valid prescription orders, board certification, or other broad privileges as specified in state regulations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23135568     DOI: 10.1093/ajhp/69.22.2002

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  2 in total

1.  Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.

Authors:  Paxton Bach; Daniel Hartung
Journal:  Addict Sci Clin Pract       Date:  2019-09-02

2.  Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center.

Authors:  David E Koren; Volodymyra Fedkiv; Huaqing Zhao; Geena Kludjian; Robert L Bettiker; Ellen Tedaldi; Rafik Samuel
Journal:  J Int Assoc Provid AIDS Care       Date:  2020 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.